TFX Quote, Financials, Valuation and Earnings

Integra Lifesciences Holdings has a net margin of -17.18% compared to Teleflex's net margin of 4.39%. Teleflex's return on equity of 1.57% beat Integra Lifesciences Holdings's return on equity of -0.45%.

Teleflex has a consensus price target of $164.32, signalling upside risk potential of 26.51%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $24.75 which suggests that it could grow by 45.67%. Given that Integra Lifesciences Holdings has higher upside potential than Teleflex, analysts believe Integra Lifesciences Holdings is more attractive than Teleflex.

Teleflex has a beta of 1.191, which suggesting that the stock is 19.095% more volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.241, suggesting its more volatile than the S&P 500 by 24.12%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1.05%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 91.2% of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are larger than Integra Lifesciences Holdings quarterly revenues of $442.6M. Teleflex's net income of -$136.7M is lower than Integra Lifesciences Holdings's net income of $19.4M. Notably, Teleflex's price-to-earnings ratio is 91.47x while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.01x versus 0.81x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of -17.18% compared to Teleflex's net margin of 28.41%. Teleflex's return on equity of 1.57% beat Intuitive Surgical's return on equity of 15.6%.

Teleflex has a consensus price target of $164.32, signalling upside risk potential of 26.51%. On the other hand Intuitive Surgical has an analysts' consensus of $619.74 which suggests that it could grow by 25.56%. Given that Teleflex has higher upside potential than Intuitive Surgical, analysts believe Teleflex is more attractive than Intuitive Surgical.

Teleflex has a beta of 1.191, which suggesting that the stock is 19.095% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.555, suggesting its more volatile than the S&P 500 by 55.506%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1.05%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 91.2% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are smaller than Intuitive Surgical quarterly revenues of $2.4B. Teleflex's net income of -$136.7M is lower than Intuitive Surgical's net income of $685.7M. Notably, Teleflex's price-to-earnings ratio is 91.47x while Intuitive Surgical's PE ratio is 77.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.01x versus 21.39x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

LeMaitre Vascular has a net margin of -17.18% compared to Teleflex's net margin of 20.07%. Teleflex's return on equity of 1.57% beat LeMaitre Vascular's return on equity of 13.81%.

Teleflex has a consensus price target of $164.32, signalling upside risk potential of 26.51%. On the other hand LeMaitre Vascular has an analysts' consensus of $105.63 which suggests that it could grow by 27.54%. Given that LeMaitre Vascular has higher upside potential than Teleflex, analysts believe LeMaitre Vascular is more attractive than Teleflex.

Teleflex has a beta of 1.191, which suggesting that the stock is 19.095% more volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.293%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1.05%. LeMaitre Vascular offers a yield of 0.82% to investors and pays a quarterly dividend of $0.20 per share. Teleflex pays 91.2% of its earnings as a dividend. LeMaitre Vascular pays out 32.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are larger than LeMaitre Vascular quarterly revenues of $55.7M. Teleflex's net income of -$136.7M is lower than LeMaitre Vascular's net income of $11.2M. Notably, Teleflex's price-to-earnings ratio is 91.47x while LeMaitre Vascular's PE ratio is 42.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.01x versus 8.58x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -17.18% compared to Teleflex's net margin of 26.88%. Teleflex's return on equity of 1.57% beat ResMed's return on equity of 25.56%.

Teleflex has a consensus price target of $164.32, signalling upside risk potential of 26.51%. On the other hand ResMed has an analysts' consensus of $267.15 which suggests that it could grow by 24.85%. Given that Teleflex has higher upside potential than ResMed, analysts believe Teleflex is more attractive than ResMed.

Teleflex has a beta of 1.191, which suggesting that the stock is 19.095% more volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1.05%. ResMed offers a yield of 0.97% to investors and pays a quarterly dividend of $0.53 per share. Teleflex pays 91.2% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are smaller than ResMed quarterly revenues of $1.3B. Teleflex's net income of -$136.7M is lower than ResMed's net income of $344.6M. Notably, Teleflex's price-to-earnings ratio is 91.47x while ResMed's PE ratio is 25.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.01x versus 6.41x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.